Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
Follow SPRB
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
48.91 | 38.75 | 96.34 | 79.08 | 88.97 | 157.15 | 3.92 | 4.11 |
Other current assets |
2.85 | 2.28 | 1.97 | 1.21 | 0.40 | 0.28 | 0.51 | 0.66 |
Total current assets |
52.11 | 44.21 | 102.18 | 83.61 | 91.90 | 160.40 | 4.65 | 4.77 |
Long-Term Investments |
— | — | — | — | 32.46 | 0.22 | — | — |
Long-term assets (Other) |
0.24 | 0.07 | 0.58 | 0.64 | 0.65 | 0.69 | 0.04 | 0.00 |
Total non-current assets |
0.91 | 1.00 | 1.76 | 2.04 | 34.59 | 2.49 | 0.04 | — |
Total Assets |
53.02 | 45.21 | 103.95 | 85.65 | 126.49 | 162.88 | 4.69 | 4.78 |
Accounts Payable |
0.94 | 1.30 | 3.33 | 1.43 | 2.82 | 3.63 | 1.88 | 2.30 |
Accrued Expenses |
9.14 | 12.33 | 14.60 | 9.40 | 6.05 | 3.58 | 1.17 | — |
Current Part of Debt |
— | 1.62 | 1.62 | 1.62 | 0.36 | 2.55 | 1.25 | — |
Current Revenue (Deferred) |
— | — | 4.91 | — | — | — | — | — |
Other current liabilities |
— | — | — | — | — | — | — | 0.41 |
Total current liabilities |
10.09 | 15.25 | 24.47 | 12.45 | 8.87 | 9.76 | 4.30 | 2.71 |
Long Term Debt (Total) |
— | 0.12 | 1.72 | 3.29 | 4.88 | 1.92 | 3.19 | — |
Non-current Liabilities (Other) |
— | 0.28 | 0.24 | 0.16 | 0.07 | 0.12 | 0.02 | — |
Total non-current liabilities |
0.42 | 1.14 | 2.97 | 4.72 | 6.24 | 3.69 | 3.21 | — |
Total liabilities |
10.51 | 16.39 | 27.44 | 17.16 | 15.12 | 13.46 | 7.52 | 2.71 |
Additional Paid In Capital |
331.75 | 279.09 | 273.74 | 218.35 | 214.69 | 210.27 | 0.66 | — |
Preferred Stock (Total) |
— | — | — | — | — | — | 27.81 | — |
Common Stock (Net) |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(289.23) | (250.27) | (197.23) | (149.31) | (103.13) | (60.84) | (31.30) | (18.21) |
Common Equity (Total) |
42.52 | 28.82 | 76.51 | 68.49 | 111.37 | 149.43 | (30.64) | (17.80) |
Shareholders Equity (Total) |
42.52 | 28.82 | 76.51 | 68.49 | 111.37 | 149.43 | (2.82) | 2.07 |
Shareholders Equity and Liabilities (Total) |
53.02 | 45.21 | 103.95 | 85.65 | 126.49 | 162.88 | 4.69 | — |
Shares (Common) |
1.37 | 0.56 | 0.55 | 0.31 | 0.31 | 0.31 | 0.01 | — |
Shareholders Equity (Tangible) |
42.52 | 28.82 | 76.51 | 68.49 | 111.37 | 149.43 | (2.82) | — |
Net Debt |
(48.91) | (37.01) | (93.00) | (74.16) | (83.73) | (152.67) | 0.52 | (4.11) |
Total Debt |
— | 1.75 | 3.34 | 4.92 | 5.24 | 4.48 | 4.45 | — |